Nyxoah Announces Partnership with ResMed in Germany
29 September 2023 - 6:30AM
Nyxoah Announces Partnership with
ResMed in GermanyCreates a continuum of
care in the German obstructive sleep apnea market
Mont-Saint-Guibert, Belgium –
September
28,
2023,
10:30pm
CET /
4:30pm
ET – Nyxoah SA
(Euronext Brussels/Nasdaq:
NYXH) (“Nyxoah” or the “Company”), a
medical technology company focused on the development and
commercialization of innovative solutions to treat Obstructive
Sleep Apnea (OSA), today announced that the Company has entered
into a partnership with ResMed Germany to increase OSA awareness
and therapy penetration in the German market.
Nyxoah and ResMed Germany will establish a
continuum of care that will educate and guide OSA patients in the
German market from diagnosis through treatment. Together, the
companies will work to accelerate patient identification and better
support patient set-up on the appropriate therapy. The companies
will collaborate on:
- OSA helplines and
direct-to-consumer marketing initiatives
- Sales and marketing efforts
targeting ENTs and sleep physicians
- Patient and clinician educational
programs and symposiums
“We are thrilled to partner with ResMed Germany,
as it strengthens further our patient-first approach to treating
obstructive sleep apnea. OSA reduces quality of life and can result
in other serious medical conditions, such as cardiovascular
disease, and type 2 diabetes. Together, ResMed Germany and Nyxoah
will heighten awareness of OSA and increase therapy penetration,”
commented Olivier Taelman, Nyxoah’s Chief Executive Officer. “The
OSA ecosystem created by this partnership will guide patients from
diagnosis to the right treatment for them, whether that is a
mandibular device, continuous positive airway pressure (CPAP), or
hypoglossal nerve stimulation (HGNS).”
"It is our joint goal to enable more patients to
receive effective, personalized therapy,” said Katrin Pucknat,
President, ResMed Germany. “Over 95 percent of patients in Germany
suffering from sleep apnea are not diagnosed or treated. In
addition, there are patients who have problems with their therapy
and just stop it without considering an alternative. The
partnership with Nyxoah will enable us to broaden the education
around therapy options and empower patients to benefit from
improved health outcomes.”
About NyxoahNyxoah is a medical
technology company focused on the development and commercialization
of innovative solutions to treat Obstructive Sleep Apnea (OSA).
Nyxoah’s lead solution is the Genio® system, a patient-centered,
leadless and battery-free hypoglossal neurostimulation therapy for
OSA, the world’s most common sleep disordered breathing condition
that is associated with increased mortality risk and cardiovascular
comorbidities. Nyxoah is driven by the vision that OSA patients
should enjoy restful nights and feel enabled to live their life to
its fullest.
Following the successful completion of the BLAST
OSA study, the Genio® system received its European CE Mark in 2019.
Following the positive outcomes of the BETTER SLEEP study, Nyxoah
received CE mark approval for the expansion of its therapeutic
indications to Complete Concentric Collapse (CCC) patients,
currently contraindicated in competitors’ therapy. Additionally,
the Company is currently conducting the DREAM IDE pivotal study for
FDA and U.S. commercialization approval.
For more information, please visit
http://www.nyxoah.com/.
Caution – CE marked since 2019.
Investigational device in the United States. Limited by U.S.
federal law to investigational use in the United States.
Forward-looking statements
Certain statements, beliefs and opinions in this press release are
forward-looking, which reflect the Company's or, as appropriate,
the Company directors' or managements' current expectations
regarding the Genio® system; planned and ongoing clinical studies
of the Genio® system; the potential advantages of the Genio®
system; Nyxoah’s goals with respect to the development, regulatory
pathway and potential use of the Genio® system; the utility of
clinical data in potentially obtaining FDA approval of the Genio®
system; and the Company's results of operations, financial
condition, liquidity, performance, prospects, growth and
strategies. By their nature, forward-looking statements involve a
number of risks, uncertainties, assumptions and other factors that
could cause actual results or events to differ materially from
those expressed or implied by the forward-looking statements. These
risks, uncertainties, assumptions and factors could adversely
affect the outcome and financial effects of the plans and events
described herein. Additionally, these risks and uncertainties
include, but are not limited to, the risks and uncertainties set
forth in the “Risk Factors” section of the Company’s Annual Report
on Form 20-F for the year ended December 31, 2022, filed with the
Securities and Exchange Commission (“SEC”) on March 22, 2023, and
subsequent reports that the Company files with the SEC. A multitude
of factors including, but not limited to, changes in demand,
competition and technology, can cause actual events, performance or
results to differ significantly from any anticipated development.
Forward looking statements contained in this press release
regarding past trends or activities are not guarantees of future
performance and should not be taken as a representation that such
trends or activities will continue in the future. In addition, even
if actual results or developments are consistent with the
forward-looking statements contained in this press release, those
results or developments may not be indicative of results or
developments in future periods. No representations and warranties
are made as to the accuracy or fairness of such forward-looking
statements. As a result, the Company expressly disclaims any
obligation or undertaking to release any updates or revisions to
any forward-looking statements in this press release as a result of
any change in expectations or any change in events, conditions,
assumptions or circumstances on which these forward-looking
statements are based, except if specifically required to do so by
law or regulation. Neither the Company nor its advisers or
representatives nor any of its subsidiary undertakings or any such
person's officers or employees guarantees that the assumptions
underlying such forward-looking statements are free from errors nor
does either accept any responsibility for the future accuracy of
the forward-looking statements contained in this press release or
the actual occurrence of the forecasted developments. You should
not place undue reliance on forward-looking statements, which speak
only as of the date of this press release.
Contacts:NyxoahDavid
DeMartino, Chief Strategy Officerdavid.demartino@nyxoah.com+1 310
310 1313
- ENGLISH_Nyxoah - RMD Parternship
Nyxoah (NASDAQ:NYXH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nyxoah (NASDAQ:NYXH)
Historical Stock Chart
From Sep 2023 to Sep 2024